1. Home
  2. SST vs MNOV Comparison

SST vs MNOV Comparison

Compare SST & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo System1 Inc.

SST

System1 Inc.

HOLD

Current Price

$4.16

Market Cap

67.7M

ML Signal

HOLD

Logo Medicinova Inc

MNOV

Medicinova Inc

HOLD

Current Price

$1.49

Market Cap

72.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SST
MNOV
Founded
2013
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.7M
72.7M
IPO Year
N/A
2005

Fundamental Metrics

Financial Performance
Metric
SST
MNOV
Price
$4.16
$1.49
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$10.00
$7.00
AVG Volume (30 Days)
30.6K
89.6K
Earning Date
11-05-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$289,784,000.00
$257,917.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.90
$1.13
52 Week High
$15.00
$2.24

Technical Indicators

Market Signals
Indicator
SST
MNOV
Relative Strength Index (RSI) 46.75 51.73
Support Level $4.07 $1.47
Resistance Level $5.00 $1.55
Average True Range (ATR) 0.43 0.05
MACD 0.12 -0.01
Stochastic Oscillator 37.12 42.11

Price Performance

Historical Comparison
SST
MNOV

About SST System1 Inc.

System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.

About MNOV Medicinova Inc

MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.

Share on Social Networks: